ÓɽðÔó´óѧµÄҽѧ¡¢ÖÆÒ©ºÍ½¡¿µ¿ÆѧÑо¿ËùKenjiro Ono£¨Ð¡Ò°ÏͶþÀÉ£©½ÌÊÚÁìµ¼µÄÑо¿Ð¡×éÓëng28ÄϹ¬Öêʽ»áÉçÏàÖú£¬ÀûÓÃпª·¢µÄÂØ¿¨Ä¹Ïà¹Øµí·ÛÑùÂÑ°×-¦ÂÔÏËά£¨Lec-PF£©ÕÉÁ¿ÏµÍ³Ö¤Ã÷£¬Óë·Ç°¢¶û´Äº£Ä¬²¡±ÈÕÕ×éÏà±È£¬°¢¶û´Äº£Ä¬²¡»¼Õß´ÓÇá¶ÈÈÏÖªÕÏ°µ½Çá¶ÈºÍÖضȳմôµÄ¸÷¸ö½×¶ÎÄÔ¼¹ÒºÖеÄLec-PFŨ¶È¶¼ÓÐËùÉý¸ß¡£±ðµÄ£¬ÕâÏîÑо¿»¹·¢Ã÷£¬ÄÔ¼¹ÒºÖÐ Lec-PFµÄŨ¶ÈÓë·´Ó¦Éñ¾±äÐÔµÄÉúÎï±ê¼ÇÎïÓÐÃ÷ÏÔµÄÏà¹ØÐÔ¡£
ÂØ¿¨Ä¹ÊÇÒ»ÖÖÆæÌصÄË«ÖØ×÷Óÿ¹Ì壬³ýÁËÇå³ý°ß¿éÍ⣬»¹Ñ¡ÔñÐÔ½áºÏµí·ÛÑùÂÑ°×-¦ÂÔÏËά£¨PF£©£¬ÊÇÖÎÁÆ°¢¶û´Äº£Ä¬²¡£¨AD£©ÒýÆðµÄÇá¶ÈÈÏÖªÕÏ°ºÍÇá¶È°¢¶û´Äº£Ä¬²¡£¨Í³³ÆΪÔçÆÚAD£©»¼ÕßµÄÒ»ÖÖÒ©Îï¡£ÕâÏîÑо¿µÄ½á¹û±êÃ÷£¬ÂØ¿¨Ä¹²¶»ñµÄPF£¨Lec-PF£©±£´æÓÚ°¢¶û´Äº£Ä¬²¡»¼ÕßµÄÄÔ¼¹ÒºÖУ¬Lec-PFÊÇÒ»Ö־綾µÄ²¡ÀíÂÑ°×£¬»áµ¼ÖÂÉñ¾ÍËÐÐÐԱ䡣ÕâÏîÑо¿½ÒʾÁËÂØ¿¨Ä¹¼õ»º°¢¶û´Äº£Ä¬²¡½øÕ¹µÄ²¿·Ö»úÖÆ¡£
»ùÓÚÕâЩ·¢Ã÷£¬Î´À´¿ÉÄÜÔÚÂØ¿¨Ä¹ÖÎÁÆÇ°ºóÕÉÁ¿ÄÔ¼¹ÒºÖÐLec PFµÄŨ¶È£¬ÒÔÆÀ¹ÀÖÎÁÆЧ¹û¡£±ðµÄ£¬ÓÉÓÚÄÔ¼¹ÒºÖÐLec-PFµÄŨ¶ÈÓë×ÜtauºÍÉñ¾¿ÅÁ£ÂÑ°×µÈÉñ¾ÍËÐÐÐÔ±ê¼ÇÎïÃÜÇÐÏà¹Ø£¬Ô¤¼ÆÕâЩ·¢Ã÷Ò²¿ÉÓÃÓÚÔ¤²â°¢¶û´Äº£Ä¬²¡»¼ÕßµÄÔ¤ºó¡£
ÕâÏîÑо¿ÓÚ2025Äê1ÔÂ6ÈÕ18:30£¨ÃÀ¹ú¶«²¿±ê׼ʱ¼ä£©Ðû²¼ÔÚ¹ú¼ÊѧÊõÆÚ¿¯¡¶Annals of Neurology¡·µÄÍøÂç°æÉÏ¡£
Ñо¿Åä¾°ºÍÄ¿µÄ
µí·ÛÑùÂÑ°×¼¶Áª¼Ù˵ÊǹØÓÚAD²¡ÒòµÄÖ÷ÒªÀíÂÛ£¬¸Ã¼Ù˵ÈÏΪ¦Âµí·ÛÑùÂÑ°×£¨A¦Â£©ÔÚÉñ¾ÔªÍâÒì³£¾Û¼¯£¬ËæºóÐγÉtauÉñ¾ÔÏËά²ø½á£¬¶ÔÉñ¾ÔªÔì³ÉËðÉË£¬²¢µ¼Ö¼²²¡±¬·¢¡£ÔÏËάÐÎ̬µÄ¦Âµí·ÛÑùÂÑ°×±ÈÏËάºÍ°ß¿éÐÎ̬¸ü¾ßÉñ¾¶¾ÐÔ£¬ºóÕßÊÇÒì³£¾Û¼¯A¦ÂµÄ×îºó½×¶Î£¬Òò´ËÈÏΪPF¿ÉÄܻᵼÖÂÉñ¾ÍËÐÐÐԱ䣨²Î¿¼ÎÄÏ×£ºAmin LºÍHarris DA.2012£©¡£ÂØ¿¨Ä¹ÊÇÒ»ÖÖ¿¹µí·ÛÑùÂÑ°×-¦ÂÔÏËά¿¹Ì壬×Ô2023ÄêÒÔÀ´Ò»Ö±ÓÃÓÚÖÎÁÆÔçÆÚAD¡£È»¶ø£¬´ËǰûÓйØÓÚÕÉÁ¿ÈËÀàÉúÎïÑù±¾ÖÐPFŨ¶ÈµÄ±¨¸æ£¬²¢ÇÒ×÷ΪÂØ¿¨Ä¹ÖÎÁưеãµÄPFÔÚÕû¸öADÁ¬ÐøÌåÖеÄÂþÑÜÇé¿öÉв»Çå³þ¡£
ÔÚÕâÏîÑо¿ÖУ¬Ñо¿Ð¡×éʹÓÃпª·¢µÄ¸ßÁéÃô¶ÈLec-PFÕÉÁ¿ÏµÍ³£¬ÕÉÁ¿ÁËÁÙ´²Ç°AD¡¢ADÒýÆðµÄÇá¶ÈÈÏÖªÕÏ°ºÍAD³Õ´ôÊÜÊÔÕßÒÔ¼°SNAP£¨ÒÉËÆ·ÇAD²¡ÀíÉúÀíѧ£©»¼ÕߺÍÈÏÖª¹¦Ð§Õý³£ÕßµÄÈËÄÔ¼¹Òº£¨CSF£©ÖÐLec-PFµÄŨ¶È£¬²¢ÆÊÎöÁËLec-PFÓëA¦Â40¡¢A¦Â42Á׵ĹØϵ¡¢ ²¢ÆÊÎöÁËLec-PFÓëA¦Â40¡¢A¦Â42¡¢Á×Ëữtau£¨p-tau£©181£¨*9£©¡¢p-tau 217¡¢×ÜtauºÍÉñ¾Á£ÂÑ°×Ö®¼äµÄ¹Øϵ¡£
Ñо¿½á¹û×ÛÊö
ADÒýÆðµÄÇá¶ÈÈÏÖªÕÏ°»ò³Õ´ô»¼Õߣ¨Í¼1ÖеÄMCI+¡¢AD+×飩µÄLec PF CSFŨ¶ÈÃ÷ÏÔ¸ßÓÚÈÏÖª¹¦Ð§Õý³£µÄ»¼Õߣ¨Í¼ÖеÄYNCºÍAMC×飩¡£
¶ÔÄÔ¼¹ÒºÖÐLec-PFµÄŨ¶ÈÓëÆäËûÄÔ¼¹Òº±ê¼ÇÎA¦Â42¡¢A¦Â42/40±ÈÖµ¡¢p-tau 181¡¢p-tau217¡¢×Ütau¡¢Éñ¾¿ÅÁ£ÂÑ°×£©Ö®¼ä½øÐÐÁËÏà¹ØÐÔÆÊÎö¡£Í¼2ÏÔʾÁËLec PFºÍÖÖÖÖCSF±ê¼ÇÎïÖ®¼äµÄSpearmanÏà¹ØϵÊý£¨95%ÖÃÐÅÇø¼ä£©¡£ÔÚËùÓÐÊÜÊÔÕßÖУ¨Í¼2ÖеĺÚÏߣ©£¬ÄÔ¼¹ÒºÖÐLec PFŨ¶ÈÓëa¦Â42¡¢a¦Â42/40±ÈÖµ¡¢p-tau 181¡¢p-tau217¡¢×ÜtauºÍÉñ¾¿ÅÁ£ÂѰ׳ÊÏà¹ØÐÔ£¬SpearmanϵÊýΪ0.2»ò¸ü¸ß¡£ÖµµÃ×¢ÒâµÄÊÇ£¬µ±½ö¹Ø×¢A¦ÂÑôÐÔ×éʱ£¨Í¼2ÖеĺìÏߣ©£¬Lec PFÓë×ÜtauºÍÉñ¾¿ÅÁ£ÂÑ°×£¨A¦Â¼¶ÁªÖÐA¦ÂÏÂÓεÄÉñ¾ÍËÐÐÐÔ±ê¼ÇÎÌåÏÖ³öºÜÇ¿µÄÏà¹ØÐÔ£¨SpearmanϵÊýΪ0.4»ò¸ü¸ß£©£¬ÕâÊÇADµÄ²¡Àíѧ¸Ä±ä£¬±êÃ÷Lec PFÊÇÒ»ÖÖÓëÉñ¾ÍËÐÐÐÔ¼²²¡Ïà¹ØµÄ¾ç¶¾²¡ÀíÂѰס£
δÀ´Éú³¤
ÔÚÂØ¿¨Ä¹ÖÎÁÆÇ°ºóÕÉÁ¿CSFÖеÄLec-PFŨ¶È¿ÉÄÜÓÐÖúÓÚÆÀ¹ÀÂØ¿¨Ä¹ÖÎÁƵÄÁÆЧ¡£±ðµÄ£¬ÓÉÓÚCSFÖÐLec-PFµÄŨ¶ÈÓëÉñ¾ÍËÐÐÐÔ±ê¼ÇÎïÃÜÇÐÏà¹Ø£¬Òò´ËËüÒ²¿ÉÄÜÓÐÖúÓÚÔ¤²âAD»¼ÕßµÄÔ¤ºó¡£
±¾Ñо¿»ñµÃÁËÈÕ±¾Ò½Ñ§Ñо¿¿ª·¢»ú¹¹£¨AMED£©³Õ´ôÖ¢Ñо¿ÓëÉú³¤×ÊÖú£¨×ÊÖúºÅ22dk0207053£©¡¢×ªÐÍÑо¿×ÊÖú£¨×ÊÖú±àºÅ23H03850£©ºÍ¿ÆѧÑо¿×ÊÖú£¨Åú×¼ºÅJP19k07965¡¢JP22k07514£©µÈÏîÄ¿µÄÖ§³Ö¡£
ͼ 1 ƾ¾ÝÁÙ´²Õï¶ÏºÍµí·ÛÑùÂÑ°×ÑôÐÔ/ÒõÐÔ·ÖÀàµÄÄÔ¼¹ÒºÂØ¿¨Ä¹Ïà¹Øµí·ÛÑùÂÑ°×ÔÏËά£¨CSF Lec-PF£©Å¨¶È

ͼ 1 ˵Ã÷
·½¿òͼÖеķ½¿òÌåÏÖËÄ·ÖλÊý¼ä¾à£¬Ë®Æ½ÏßÌåÏÖÖÐλÊý¡£¸÷×éËõд£º YNC£¨ÄêÇáÕý³£±ÈÕÕ×éµí·ÛÑùÂÑ°×ÒõÐÔ£©¡¢AMC£¨ÄêÁäÆ¥Åä±ÈÕÕ×éµí·ÛÑùÂÑ°×ÒõÐÔ£©¡¢CI-£¨ÈÏÖª¹¦Ð§ÊÜËð×éµí·ÛÑùÂÑ°×ÒõÐÔ£©¡¢CU+£¨ÈÏÖª¹¦Ð§Î´ÊÜËð×éµí·ÛÑùÂÑ°×ÑôÐÔ£©¡¢MCI+£¨Çá¶ÈÈÏÖª¹¦Ð§ÊÜËð×éµí·ÛÑùÂÑ°×ÑôÐÔ£©¡¢AD+£¨AD ³Õ´ô×éµí·ÛÑùÂÑ°×ÑôÐÔ£©¡¢CSF£¨ÄÔ¼¹Òº£©¡£
*p < 0.05
ͼ 2 ÄÔ¼¹Òº±ê¼ÇÎïÓëÄÔ¼¹ÒºÂØ¿¨Ä¹Ïà¹Øµí·ÛÑùÂÑ°×ÔÏËά£¨CSF Lec-PF£©µÄÏà¹ØÐÔ

ͼ2˵Ã÷
ºÚÏߺͺìÏß»®·ÖÌåÏÖÕû¸öÊÜÊÔÕß×éºÍµí·ÛÑùÂÑ°×ÑôÐÔÊÜÊÔÕß×éCSF Lec-PFÓë¸÷ÄÔ¼¹Òº±ê¼ÇÎïÖ®¼ä˹Ƥ¶ûÂüÏà¹ØϵÊýµÄ95%ÖÃÐÅÇø¼ä (CI)¡£ºÚµãºÍºìµãÌåÏÖ˹Ƥ¶ûÂüÏà¹ØϵÊýµÄÖÐÖµ¡£ºÚÏߺͺìÏßÖ®¼äµÄ¾Þ´ó²î±ð·´Ó¦ÁËA¦Â ÑôÐÔ»òÒõÐÔ״̬µÄÏÔÖøÓ°Ïì¡£
ÔÚÕâÏîÆÊÎöÖУ¬ËùÓÐÊÜÊÔÕߣ¨ºÚÏߣ©µÄCSF Lec-PFÓëËùÓвⶨµÄÉúÎï±ê¼ÇÎ¼´A¦Â42¡¢A¦Â42/40±ÈÖµ¡¢p-tau 181¡¢p-tau 217¡¢×Ü-tauºÍÉñ¾¿ÅÁ£ÂÑ°×£©Ö®¼äµÄÏà¹ØϵÊý¾ùΪ0.2»ò¸ü¸ß£¬±êÃ÷ CSF Lec-PF ÓëÕâЩÉúÎï±ê¼ÇÎïÖ®¼ä±£´æÏÔÖøÏà¹ØÐÔ¡£ÔÚµí·ÛÑùÂÑ°×ÑôÐÔ×飨ºìÏߣ©ÖУ¬CSF Lec-PFÓëCSF total-tauµÄSpearmanÏà¹ØϵÊý»®·ÖΪ0.634£¨CI£º0.409-0.786£©£¬CSF Lec-PFÓëCSF neurograninµÄSpearmanÏà¹ØϵÊý»®·ÖΪ0.434£¨CI£º0.260-0.581£©£¬±êÃ÷CSF Lec-PFÓëÕâÁ½ÖÖÉúÎï±ê¼ÇÎïÖ®¼ä±£´æºÜÇ¿µÄÏà¹ØÐÔ¡£ÁíÒ»·½Ã棬CSF Lec-PFÓëÄÔA¦ÂÀÛ»ýÉúÎï±ê¼ÇÎïCSF A¦Â42ºÍCSF A¦Â42/40±ÈÖµÖ®¼äµÄÏà¹ØÐÔ¶¼Ïà¶Ô½ÏµÍ¡£Õâ±êÃ÷£¬CSF Lec-PFµÄº¬Á¿ÓëÉñ¾ÍËÐÐÐÔ±äµÄ¹Øϵ±È´óÄÔÖÐA¦ÂµÄ»ýÀÛ¸üΪÃÜÇС£
ÎÄÕ·¢ÐÄÇé¿ö£º
ÆÚ¿¯Ãû³Æ£ºAnnals of Neurology
ÎÄÕÂÌâÄ¿: Lecanemab-associated amyloid-¦Â protofibril in cerebrospinal fluid correlates with
biomarkers of neurodegeneration in Alzheimer¡¯s disease (Cerebrospinal fluid (CSF) lecanemab-associated amyloid protofibril concentrations correlate well with neurodegenerative biomarkers in AD)
×÷Õß: Moeko Noguchi-Shinohara, Kazuyoshi Shuta, Hidetomo Murakami, Yukiko Mori, Junji Komatsu, Chizuru Kobayashi, Steven Hersch, Kanta Horie, Kenjiro Ono
Ðû²¼ÈÕÆÚ£ºJanuary 6, 2025 (US Eastern Standard Time).
DOI: 10.1002/ANA.27175
ÐÅÏ¢ÁªÂ磺
¡ö Regarding research content
Kanazawa University
Professor Kenjiro Ono
TEL: +81-(0)76-265-2292
Email: onoken@med.kanazawa-u.ac.jp
Associate Professor Moeko Shinohara
TEL: +81-(0)76-265-2292
Email: m-nohara@med.kanazawa-u.ac.jp
Eisai Co., Ltd.
Kanta Horie
E-mail: kanta_horie@eisai.com
¡ö Public Relations Officer
General Affairs Section, General Affairs Division, Medical, Pharmaceutical and Health Sciences
Administration Department, Kanazawa University
Rina Yamada
TEL: +81-(0)76-265-2109
E-mail: t-isomu@adm.kanazawa-u.ac.jp
Eisai Co., Ltd. PR Department
TEL: +81-(0)3-3817-5120
±àºÅ£ºECN2025-0002